Back to MRKView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Bacterial Infections
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA2/13/2012
Colobreathe
Colobreathe is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged six years and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
MK-8748Phase 3
Diabetic Retinopathy
alendronate with cholecalciferolPhase 3
Osteoporosis
Simvastatin 20 mg dailyPhase 3
Cardiovascular Disease
EpinephrinePhase 3
Malignant Neoplasms of Male Genital Organs
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)Phase 3
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts